Clinical Trial Update: Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating omacetaxine in intermediate-1 and higher risk myelodysplastic syndrome after failure of hypomethylating therapy; study completed with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Omacetaxine (omacetaxine mepesuccinate)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-06-09